🌎 Headlines and Analyst Ratings for 12/29/2023

Ratings changes for AcelRx Pharmaceuticals, Signature Bank, Adaptimmune Therapeutics, Huntington Bancshares, Richardson Electronics, Mirati Therapeutics, Heritage Financial and more...Upgrade to MarketBeat All Access to get early delivery, personalized stock alerts, portfolio monitoring tools, and more. Start Your Free Trial. Unsubscribe. VIEW MY PORTFOLIO December 29th, 2023     Get These Top Performing Stocks At A Discount Right Now! (ad) As you know, the stock market has been volatile lately, and there's a lot of uncertainty in the air. But we want to assure you that this is not the time to panic. In fact, it's the time to be buying stocks. By clicking link you are subscribing to The Darwin Investor Network and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here. Download Our Free Report Here Today's Top Stories Synopsys stock: Unsung hero of the AI revolution South Carolina nuclear plant's cracked pipes get downgraded warning from nuclear officials "Chilling War Games Show US Forces Crushed" – FOX NEWS (Behind the Markets) Microsoft is new cybersecurity titan, challenging big tech rivals South Carolina nuclear plant's cracked pipes get downgraded warning from nuclear officials Cruise lines navigate from worst to first in 2023 surge Stock market today: Stocks slip on the final trading day of a surprisingly good year on Wall Street We're In The Final Inning Of America's First-Ever Cash Bubble (Tradesmith) Small-cap surge: Outpacing large caps on hopes for '24 rate cuts What stores are open and closed for New Year's Eve 2023? See hours for Walmart, Target, CVS and more Bristol Myers Squibb's big buys: $18.1 billion in 2 biotech deals Stock market today: U.S. futures are little changed as Wall Street wraps up surprisingly good year Quick Links MarketBeat All Access My MarketBeat Account Settings Mobile App Analyst Ratings Best way to buy gold today (not what you'd think) (ad) With so many strange events happening across the economy (longest bear market for bonds since Civil War... unprecedented bank closures... and soaring prices) – it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – without ever touching an ETF, mining stock, or even bullion. Full details here. Your Watchlist You have not added any stocks to your watchlist. Click here to add stocks to your watchlist. Fraud Expert: Dump these three popular stocks (ad) A major (and legal) market manipulation scheme is about to play out. It could cost you a fortune – or double your money. You choose. Find out what he knows, here. Find out what he knows, here. Analysts' Downgrades Lyft (NASDAQ:LYFT) was downgraded by analysts at Nomura from a "neutral" rating to a "reduce" rating. They now have a $13.00 price target on the stock, up previously from $11.70. This represents a 12.5% downside from the current price of $14.85. Uber Technologies (NYSE:UBER) was downgraded by analysts at Nomura from a "buy" rating to a "neutral" rating. They now have a $62.00 price target on the stock, up previously from $59.00. This represents a 0.2% upside from the current price of $61.90. View today's most recent analysts' downgrades at MarketBeat.com Elon Musk May Have Just Changed Everything (ad) Quantum computing, 3D Printing and Gene-Editing are 3 most disruptive pieces of technology in recent times. None compare to a project Elon Musk released which could mint the world’s first trillionaire.  Learn all about it here. Analysts' New Coverage Annovis Bio (NYSE:ANVS) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $36.00 price target on the stock. This represents a 92.0% upside from the current price of $18.75. Annovis Bio (NYSE:ANVS) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $36.00 price target on the stock. This represents a 92.0% upside from the current price of $18.75. View today's most recent analysts' new coverage at MarketBeat.com Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. START YOUR 30-DAY FREE TRIAL Calendars from MarketBeat U.S. Analyst Ratings Corporate Buybacks Cryptocurrencies Dividend Declarations Earnings Announcements Economic Reports Gap Up/Down Stocks Insider Trades Initial Public Offerings (IPOs) Most Active Stocks Percentage Gainers/Decliners Sector Performance Short Interest Unusual Options Volume Unusual Trading Volume Upgrade Your Subscription Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET. UPGRADE NOW Manage Your Watchlist View and add up to five holdings to your watchlist. VIEW MY PORTFOLIO Join Our Facebook Group Join MarketBeat's free stock discussion and trading idea group on Facebook. JOIN NOW

Thank you for subscribing to MarketBeat! We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: This is the #1 Stock to Buy for the AI Tidal Wave